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Abstract
Background: The neuroinflammatory responses in the spinal cord following bone cancer development have been
shown to play an important role in cancer-induced bone pain (CIBP). Lipoxins (LXs), endogenous
lipoxygenase-derived eicosanoids, represent a unique class of lipid mediators that possess a wide spectrum of
anti-inflammatory and pro-resolving actions. In this study, we investigated the effects of intrathecal injection with
lipoxin and related analogues on CIBP in rats.
Methods: The CIBP model was induced by intra-tibia inoculation of Walker 256 mammary gland carcinoma cells.
Mechanical thresholds were determined by measuring the paw withdrawal threshold to probing with a series of
calibrated von Frey filaments. Lipoxins and analogues were administered by intrathecal (i.t.) or intravenous (i.v.)
injection. The protein level of LXA4 receptor (ALX) was tested by western blot. The localization of lipoxin receptor in
spinal cord was assessed by fluorescent immunohistochemistry. Real-time PCR was carried out for detecting the
expression of pro-inflammatory cytokines.
Results: Our results demonstrated that: 1) i.t. injection with the same dose (0.3 nmol) of lipoxin A4 (LXA4), lipoxin
B4 (LXB4) or aspirin-triggered-15-epi-lipoxin A4 (ATL) could alleviate the mechanical allodynia in CIBP on day 7 after
surgery. ATL showed a longer effect than the others and the effect lasted for 6 hours. ATL administered through i.v.
injection could also attenuate the allodynia in cancer rats. 2) The results from western blot indicate that there is no
difference in the expression of ALX among the naive, sham or cancer groups. 3) Immunohistochemistry showed
that the lipoxin receptor (ALX)-like immunoreactive substance was distributed in the spinal cord, mainly co-localized
with astrocytes, rarely co-localized with neurons, and never co-localized with microglia. 4) Real-time PCR analysis
revealed that, compared with vehicle, i.t. injection with ATL could significantly attenuate the expression of the
mRNA of proinflammatory cytokines (IL-1β and TNF-α) in the spinal cord in CIBP.
Conclusions: Taken together, the results of our study suggest that LXs and analogues exert strong analgesic effects
on CIBP. These analgesic effects in CIBP are associated with suppressing the expression of spinal proinflammatory
cytokines.
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Background
A recent study on the prevalence of pain in cancer in 11
European countries and Israel found that 56% of patients
suffered moderate to severe pain at least monthly, and
69% of patients reported pain-related difficulties with
everyday activities [1,2]. Although pain has been studied
in depth for decades, the pain associated with cancer is
still under-treated and disruptive to the patient’s quality
of life. Therefore, it is imperative to investigate the mechan-
ism of cancer pain and to find effective therapy. However,
because of the complicated mechanism of cancer pain, the
underlying mechanisms are still unclear. It has been
reported that cancer-induced bone pain (CIBP) is a unique
pain state showing physiological characteristics of both in-
flammatory and neuropathic pain and changes in dorsal
horn-cell phenotype [3-8]. As compared with neuropathic
pain and inflammatory pain, CIBP might display physio-
logical and pathological changes similar to those observed
in the spinal cord. After the cancer cells invaded or were
injected, an inflammatory response is inevitably observed,
while in the later phase, the nervous system is invaded by
cancer cells or other inflammatory factors and displays
characteristic inflammatory responses [6,7,9,10]. Rats with
CIBP display rapid expression and release of multiple in-
flammatory mediators, such as prostaglandin (PGE2), nerve
growth factor (NGF) and proinflammatory cytokines in-
cluding interleukin-1β (IL-1β), interleukin-6 (IL-6) and
tumor necrosis factor-α (TNF-α), at the spinal cord. These
mediators participate in the pathogenesis of CIBP [10-12].
Recently, accumulating evidence supports an important
role of spinal non-neuronal cells, such as astrocytes and
microglia, in the regulation of nociception [12,13]. Cer-
tainly, neuroinflammation is a significant characteristic of
the entire pathological process of CIBP.
Accumulating evidence shows that most inflammatory
processes are self-limiting and self-resolving systems, which
are known as an active endogenous process aimed at pro-
tecting the host from exacerbated inflammation [14-16].
The outcome depends on the balance between pro-
inflammatory mediators and anti-inflammatory mediators
in vivo [17]. Lipoxins (LXs) belong to a class of eicosanoid
that is generated from arachidonic acid via the sequential
actions of lipoxygenases and subsequent reactions to yield
specific trihydroxytetraene-containing eicosanoids [18].
As the first recognized class of anti-inflammatory lipid-
based autacoids, LXs mediate a number of processes,
including the regression of pro-inflammatory cytokine
production, inhibition of cell proliferation, promotion of
the recruitment of monocytes and stimulation of non-
phlogistic phagocytosis of apoptotic leukocytes by
monocyte-derived macrophages, suggesting that lipoxins
may act as endogenous ‘braking signals’ in host defense,
inflammation and hypersensitivity reactions [17,19,20].
LXA4 and LXB4 are positional isomers that possess
potent cellular and in vivo actions [21]. Moreover, aspirin
has a direct impact on the LX circuit by triggering the bio-
synthesis of endogenous epimers of LXs, termed aspirin-
triggered-15-epi-lipoxin A4 (ATL), which share the potent
anti-inflammatory actions of LXs [15,21,22].
It has been reported that i.t. injection of LXs can at-
tenuate inflammatory pain and neuropathic pain [23,24].
Due to the sustained and robust spinal neuroinflamma-
tion that characterizes CIBP, we hypothesized that i.t. in-
jection with LXs may be a novel strategy that mimics
the action of endogenous anti-inflammatory and pro-
resolution lipid mediators to alleviate CIBP. Therefore,
the present study was designed to explore the possible
analgesic effect of LXs on the rat model of CIBP.
Methods
Animals
Experiments were performed on pathogen-free adult female
Sprague–Dawley (SD) rats (Shanghai Laboratory Animal
Center, Chinese Academy of Sciences, Shanghai, China)
weighing 160 g to 180 g. Animals were housed in groups of
4 to 6 per cage and maintained on a 12:12 hour light–dark
cycle and constant room conditions (temperature, 22 ±
2°C; humidity, 55% ± 10%) with free access to food and
water. Prior to experimental manipulation, rats were habi-
tuated in the animal room for at least one week after deliv-
ery. All experimental protocols and animal-handling
procedures were performed according to protocols
approved by the Animal Care and Use Committee
(ACUC) of Fudan University and were consistent with
the National Institutes of Health Guide for the Care and
Use of Laboratory Animals and the International Asso-
ciation for the Study of Pain’s (IASP) guidelines for pain
research [24]. All efforts were made to minimize the
number of animals used and to minimize their suffering.
Preparation of cells
Walker 256 rat mammary gland carcinoma cells (gener-
ously provided by the Institute of Radiation Medicine,
Fudan University) were injected into the abdominal cav-
ities of female SD rats weighing 60 g to 80 g (2 × 107
cells/0.5 ml). After 6 to 7 days, cancerous ascites was
harvested in a sterile fashion, and the carcinoma cells
were subsequently washed with PBS, pH=7.2, three
times by centrifugation for 3 minutes at 1200 rpm. The
pellet was resuspended with PBS and adjusted to an ap-
propriate concentration (1 × 108/ml). The cell suspen-
sion was maintained on ice until injection.
Surgical procedure
As previously described [5,25], rats (except the naive
group) were anesthetized with chloral hydrate (400 mg/kg,
i.p.). Superficial incisions were made in the skin overlying
the patella after disinfection with 75% v/v ethanol in order
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to expose the tibia head with minimal damage. After
Walker 256 carcinoma cells were prepared, 4 μl of cells
followed by 4 μl PBS were slowly injected into the right
tibia cavity of each rat using a 10-μl microinjection syr-
inge. The syringe was left in place for an additional two
minutes to prevent the carcinoma cells from leaking out
along the injection track. The injection site was closed
using bone wax as the syringe was removed to prevent
tumor cell overflow. The sham group rats were treated in
the same way and injected with 8 μl of PBS instead of
tumor cells. All rats were given gentamycin (40 mg/kg,
i.p.) for three consecutive days to avoid wound infection.
Drug administration
To determine the effects of LXs on the bone cancer-
induced mechanical allodynia, a single dose of LXA4
(Merck, Darmstadt, Germany), ATL (Merck, Darmstadt,
Germany), LXB4 (Cayman, Ann Arbor, MI, USA) or
normal saline (NS) was administered in a volume of
20 μl to rats via lumbar puncture, as previously reported
[26]. Briefly, the rats were anesthetized with isoflurane.
The lumbar region was disinfected with 75% v/v ethanol
after hair shaving, and the intervertebral spaces were
widened by placing the animal on a plexiglass tube.
Next, a 29-gauge microinjection syringe needle filled
with 20 μl of drug was inserted via the L5-6 interspace.
The correct subarachnoid positioning of the tip of the
needle was verified by a tail- or paw-flick response im-
mediately after inserting the needle.
Behavioral test
The paw withdrawal threshold (PWT) was measured
using von Frey hairs (Stoelting, Wood Dale, Illinois,
USA) Each rat was placed individually into a plexiglass
chamber containing 1.5-mm diameter holes in a 5-mm
grid of perpendicular rows throughout the entire area of
the metal platform [27]. After acclimation to the test
chamber, a series of eight calibrated von Frey hairs (0.4,
0.6, 1.4, 2, 4, 6, 8 and 15 g) were applied to the central
region of the plantar surface of one hind paw. The tester
was blinded with respect to group. Each von Frey hair was
held for approximately 1 to 2 seconds with a 5-minute
interval between applications. A trial began with the appli-
cation of 2.0 g von Frey hair. A positive response was
defined as a brisk withdrawal of the hind paw upon stimu-
lation. When a positive response to a given hair occurred,
the next lower von Frey hair was applied, and when a
negative response occurred, the next higher hair was ap-
plied. The tests consisted of five more stimuli after the
first change in response occurred, and the PWT was con-
verted to the tactile response threshold using an adapta-
tion of the Dixon up-down paradigm, as described
previously [28]. All the tests were performed in a blinded
fashion with respect to the drugs injected.
Western blot
The L4-L5 segments of the spinal cord were homoge-
nized and subjected to SDS-PAGE. Membranes were
incubated with antibodies against ALX (1:4000, United
States Biological, Swampscott, Massachusetts, USA). The
signal was detected with chemiluminescent reagents (ECL
kit, Pierce, Rockford, Illinois, USA). The membranes were
re-blotted with GAPDH (1:10000, KangCheng, Shanghai,
China). The intensity of immunoreactive bands was quan-
tified using ImageQuant software (Molecular Dynamics).
Immunohistochemistry
On day 11 after surgery, rats were deeply anesthetized
with chloral hydrate (400 mg/kg, i.p.) and perfused intra-
cardially with saline followed by 4% paraformaldehyde in
0.1 M phosphate buffer (PB, pH 7.4). The L4-L5 seg-
ments of the spinal cord were subsequently removed,
post-fixed in the same fixative for 4 hours at 4°C, and
immersed in a 10% to 30% sucrose solution in PB gradi-
ent for 24 to 48 hours at 4°C for cryoprotection. Trans-
verse spinal sections (free-floating, 30 μm) were cut in a
freezing microtome (Leica CM1900, Munich,Germany)
and processed for immunofluorescence. All of the sec-
tions were blocked with 10% normal goat serum in
0.01 M PBS (pH 7.4) with 0.3% Triton-X-100 for 1 hour
Table 1 Seqences of the forward and reverse primers and PCR conditions used for RT-PCR
Genbank accession
numbers
Target gene Primers PCR conditions (temperature/time)
Denature Anneal Extend
NM_017008 GAPDH Foward: 50cccttcattgacctcaactac-30 94°C/45 seconds 60°C/1 minute 72°C/1 minute
Reverse: 50-cttctccatggtggtgaagac-30
NM_031512 IL-1β Forward: 50-atgagagcatccagcttcaaatc-30 94°C/45 seconds 58°C/1 minute 72°C/1 minute
Reverse: 50-cacactagcaggtcgtcatcatc-03
NM_012589 IL-6 Forward: 50-gacaaagccagagtccttca-30 94°C/45 seconds 58°C/1 minute 72°C/1 minute
Reverse: 50-actaggtttgccgagtagac-30
X66539 TNF-α Forward: 50-cgagatgtggaactggcaga-30 94°C/45 seconds 58°C/1 minute 72°C/1 minute
Reverse: 50-ctacgggcttgtcactcga-30
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Figure 1 (See legend on next page.)
Hu et al. Journal of Neuroinflammation 2012, 9:278 Page 4 of 12
http://www.jneuroinflammation.com/content/9/1/278
at 37°C and incubated overnight at 4°C with rabbit
anti-ALX (1:400, United States Biological, Swampscott,
Massachusetts, USA) primary antibody in PBS with 1%
normal goat serum and 0.3% Triton X-100. Following
three 15-minute rinses in 0.01 M PBS, the sections were
incubated in Alexa Fluor 594-conjugated secondary anti-
body (red, 1:1000, Invitrogen, Carlsbad, California, USA)
for 1 hour at 37°C and were washed in PBS. Omission of
the primary antibody served as a negative control. The
specificity of the anti-ALX antibody was also tested by
Western Blot. For double immunofluorescence, sections
were incubated with a mixture of rabbit anti-ALX and
mouse anti-NeuN (1:500, Millipore, Billerica, Marriott,
USA), mouse anti-CD11b (1:200, Chemicon, Billerica,
Marriott, USA), mouse anti-GFAP (1:1000, Thermo, Wal-
tham, Massachusets, USA) antibodies respectively at 37°C
for 1 hour and at 4°C overnight. Next, the sections were
incubated with a mixture of goat Alexa Fluor™ 594-
conjugated (red, 1:1000, Invitrogen) and goat Alexa
Fluor™ 488-conjugated (green, 1:1000, Invitrogen) sec-
ondary antibodies for 1 hour at 37°C. All sections were
coverslipped with a mixture of 80% glycerin in 0.01 M
PBS, and images were captured using a multiphoton laser
point scanning confocal microscopy system (Olympus
Fluoview FV1000, Leica TCS SP5, Germany).
All of the testing (including behavior, western blot,
immunohistochemistry and real-time PCR) was con-
ducted by experimenters who were blind to the experi-
mental conditions.
Real-time quantitative PCR
Total RNA was isolated from L4-L6 spinal cord using
TRIzol reagent (Invitrogen) according to the manufac-
turer’s instructions. Quantification of mRNA levels of
IL-1β, IL-6, TNF-α and GAPDH were analyzed by SYBR
Green qRT-PCR detection (iCycler iQW real-time PCR
detection system, Bio-Rad, Hercules City, California,
USA), with each sample being run in duplicate. Samples
of cDNA from naive, cancer with NS and cancer with
ATL animals 2 hours after drug injection were analyzed
simultaneously by real-time PCR. The PCR mixture was
prepared by using the multiplex real-time PCR protocol
according to the manufacturer’s instructions. A total of
2 μl of reverse transcription product from each sample
was used as the template in a 25-μl reaction mixture.
The size and sequence of each primer and the number
of cycles used are given in Table 1 [29]. The standard
curve of each primer showed that the amplification effi-
ciency was 90% to 100% (data not shown). Upon com-
pletion of the PCR, the amount of target message in
each sample was estimated based on the threshold cycle
number (Ct). Average Ct values were normalized to aver-
age Ct values for GAPDH mRNA from the same cDNA
preparations. These values were entered into the equation
2−ΔΔCT to solve for the relative exponential PCR amplifi-
cation of each gene for each animal [30,31]. The results
presented in this study are expressed as fold increases over
control values.
Statistical analysis
All data are presented as mean ± standard error of the
mean (SEM). The statistical significance of differences
between groups was analyzed with Student’s T-test or
one-way analysis of variance (ANOVA) following the
least-significant difference (LSD) post-test or Bonferroni
post-test. P<0.05 was set as the threshold of significance.
Results
The development of CIBP
After the baseline behavioral test, the rats in the cancer
group received carcinoma cells (Walker 256 carcinoma
cells, 4×105) that were injected into the right tibia cavity,
as previously described (day 0). The sham group received
an equal volume of PBS (day 0). The naive group received
no treatment. In order to assess the development of
mechanical allodynia in CIBP, PWT was tested on day 3,
7, 9 and 11after surgery. On day 3 after surgery, the rats in
the cancer group displayed a profound decrease in PWT
to von Frey hair stimulation in the ipsilateral right limb
(P<0.001, Bonferroni test) compared with the sham group.
This decrease lasted until day 11 when the observation
ended. In contrast, there was no significant difference in
(See figure on previous page.)
Figure 1 Lipoxins and analogues alleviate mechanical allodynia in the CIBP model induced by intra-tibia injection of Walker 256
carcinoma cells (4×105). (A) The time course of the development of mechanical allodynia after cancer cell inoculation. +++P<0.001 versus the
sham group (by Bonferroni test). (B) Comparisons were also made between the effects of the ATL, LXA4 and LXB4 treatments on rats with CIBP
on day 7 after surgery. Data are expressed as means ± SEM. *P<0.05, **P<0.01, ***P<0.001 versus cancer + NS (by Bonferroni test). ##P<0.01,
###P<0.001 versus cancer +ATL (by T-test). (C) Effects of i.t. LXA4, LXB4 and ATL on the mechanical allodynia of naive rats (by Bonferroni test).
(D) Anti-allodynia effects of i.t.ATL at different doses on rats with CIBP. On day 11 after surgery, the cancer groups were given different doses of
ATL by i.t. injection. Note that the dose of 0.45 nmol showed a better and longer analgesic effect from 2 to 8 hours than the other doses.
*P<0.05, **P<0.01, ***P<0.001 versus cancer + NS (by LSD test). #P<0.05 versuscancer + ATL 0.45 nmol (by T-test). (E) Anti-allodynia effects of i.v.
ATL at different doses on rats with CIBP. On day 11 after surgery, the three groups were injected i.v. with NS or different doses of ATL (10 nmol/
kg or 120 nmol/kg). #P<0.05 versus cancer +ATL 30 nmol/kg (by T-test). Data are expressed as means ± SEM. *P<0.05, **P<0.01, ***P<0.001 versus
cancer + NS (by Bonferroni test).ATL, aspirin-triggered-15-epi-lipoxin A4; CIBP, cancer-induced bone pain; i.t., intrathecal; i.v., intravenous; LSD,
least-significant difference; LX, lipoxin; NS, normal saline; SEM, standard error of the mean.
Hu et al. Journal of Neuroinflammation 2012, 9:278 Page 5 of 12
http://www.jneuroinflammation.com/content/9/1/278
PWT between the naive group and the sham group at the
different time points (P>0.05, Bonferroni test) (Figure 1A).
Intrathecal injection with LXA4, ATL and LXB4 reduces
the mechanical allodynia in CIBP
In order to examine the analgesic effects of LXs on the
mechanical allodynia in CIBP, on day 7 after surgery,
cancer rats were randomly divided into four groups: one
group was treated i.t. with NS (20 μl) as vehicle, and the
others were treated i.t. with equal doses of LXA4, LXB4
or ATL (0.3 nmol/20 μl). The ipsilateral PWT was tested
at 2, 4 and 6 hours after drug administration. Compared
with vehicle-treated animals, the PWT was profoundly
increased from 2 to 6 hours in the ATL-injected animals
Figure 2 Localization and expression level of ALX among the naive, sham and cancer groups on day 11 after surgery. (A) Western blot
detection of ALX expression in the spinal cord of rats. Data are expressed as means ± SEM (n=4) (by Bonferroni test). (B) Photomicrographs
showing the expression of ALX in the dorsal horn of the ipsilateral spinal cord of rats. Immunohistological staining was carried out on the spinal
cord sections from the naive (a-b), sham (c-d) and cancer (e-f) groups. Bar 100 μm. ALX, lipoxin A4 receptor; SEM, standard error of the mean.
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(P<0.001, Bonferroni test), while this measure was sig-
nificantly increased after 2 hours in the LXA4-injected
animals (P<0.01, Bonferroni test) and in the LXB4-
injected animals (P<0.05, Bonferroni test) (Figure 1B).
However, i.t. treatment with equimolar doses of LXA4,
LXB4 or ATL did not alter the nociceptive thresholds of
the naive animals (P>0.05) (Figure 1C, Bonferroni test).
Intrathecal injection with different doses of ATL alleviates
mechanical allodynia in CIBP
We assessed the effects of i.t. with different doses of
ATL on the ipsilateral PWT of animals on day 11 after
surgery. Cancer rats were randomly divided into four
groups: one group was treated with i.t. NS (20 μl) as ve-
hicle, and the others were treated i.t. with different doses
of ATL (0.03, 0.3 or 0.45 nmol/20 μl). PWT was tested
at 2, 4, 6, 8 and 12 hours after drug administration.
Compared with the vehicle-treated animals, the animals
treated i.t. with ATL (0.03, 0.3 or 0.45 nmol) showed
significant increases in PWT from 2 to 6 hours (P<0.05,
LSD test). The dose of 0.45 nmol showed longer effects
(for 8 hours) (Figure 1.D, LSD test). These results indi-
cate that a single administration of ATL could reduce
the mechanical allodynia in CIBP.
Intravenous ATL attenuates mechanical allodynia in CIBP
To assess the possible analgesic effect of systemically
administered ATL, the effects of i.v. ATL on the mech-
anical allodynia in cancer rats were observed on day 11
after surgery. From 1 to 4 hours after the injection of 30
or 120 nmol/kg ATL, the PWT increased significantly
compared with vehicle (Figure 1E, Bonferroni test) indi-
cating an anti-allodynic effect of i.v. ATL in cancer rats.
Expression of ALX in the spinal cord
The possible distribution of ALX in the spinal cord was
detected by immunohistochemistry. Lumbar spinal cords
from the naive, sham and cancer groups were sectioned
Figure 3 Photomicrographs showing the expression of GFAP (astrocyte marker) (green) and ALX (red) on the dorsal horn of the
ipsilateral spinal cord of rats. Examples of double labeling are indicated with white arrows. Immunohistological processing of spinal cord
sections from the naive (A-C), sham (D-F) and cancer (G-I) groups showed obvious co-localization of ALX-like immnoreactivity and the astrocyte
marker GFAP (n=4). Bar 100 μm. ALX, lipoxin A4 receptor; GFAP, glial fibrillary acidic protein.
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and incubated with ALX antibody. Similar and moderate
ALX-like immunoreactivity was observed in the spinal
cord of naive, sham and cancer rats (Figure 2B). No sig-
nificant difference in the level of the expression of the
ALX protein was found among naive, sham or cancer
groups (Figure 2A). Double labeling of spinal sections
revealed that the ALX-like immunoreactivity was mainly
co-localized with the astrocyte marker glial fibrillary
acidic protein (GFAP; Figure 3), partly co-localized with
the neuronal marker NeuN (Figure 4) but not with the
microglia marker CD11B (Figure 5).
Effects of ATL on the expression of the mRNA of
pro-inflammatory cytokines in CIBP
To investigate the molecular mechanisms associated
with the anti-allodynic effect of ATL in rats with CIBP,
we evaluated the expression of the mRNA of several
pro-inflammatory mediators, including IL-1β, IL-6 and
TNF-α in the spinal cord by real-time PCR. Rats were
randomly divided into three groups: naive, cancer with
NS and cancer with ATL. As compared with the naive
group, cancer with saline groups showed significant
increases in pro-inflammatory mediators (P<0.01, LSD
test). I.t. injection of ATL to the rats with CIBP signifi-
cantly decreased the expression of the mRNA of IL-1β
and TNF-α (P<0.05, LSD test) (Figure 6).
Discussion
The present study demonstrated that i.t. treatment with
LXA4, LXB4 or ATL could significantly alleviate the
mechanical allodynia in CIBP. ATL showed the longest
and most potent analgesic effect compared to LXA4 and
LXB4. Further analysis showed that the increased ex-
pression of IL-1β and TNF-α in CIBP were significantly
inhibited after i.t. injection with ATL. Immunohisto-
chemistry revealed that ALX was mainly co-localized
with the astrocytes and partly co-localized with the neu-
rons but not with microglia. The present study suggests
Figure 4 Photomicrographs showing the expression of NeuN (neuron marker) (green) and ALX (red) on the dorsal horn of the
ipsilateral spinal cord of rats. Examples of double labeling are indicated with white arrows. Immunohistological processing of spinal cord
sections from the naive (A-C), sham (D-F) and cancer (G-I) groups showed that ALX-like immunoreactivity is partly co-localized with the neuronal
marker NeuN (n=4). Bar 100 μm. ALX, lipoxin A4 receptor.
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that ATL might exert its anti-neuroinflammation effects
in CIBP through the ALX receptor expressed on astro-
cytes and/or some neurons at the spinal cord.
Many reports suggest that the ALX was identified and
cloned in various cell types, including polymorphonuclear
cells, monocytes, activated T cells, intestinal enterocytes
and synovial fibroblasts [14,22]. In our study, the analgesic
effects observed after i.t. injection with LXA4, LXB4 and
ATL indicated that this class of lipid mediators acts on spe-
cific targets in the spinal cord. Recently, evidence from two
independent groups revealed the existence of ALX expres-
sion in rat primary astrocytes [24,32] and microglia [33] at
both the mRNA and protein levels. However, the present
results showed that the ALX was mainly co-localized with
astrocytes, sometimes co-localized with neurons, and did
not co-localize with microglia, which is inconsistent with
the previous reports. These discrepancies may be due to
the different models and contexts (in vivo or in vitro). It
has been demonstrated that non-neuronal cells may play
an important role in the spinal facilitation of pain proces-
sing [34,35], and LXs may act through ALX distributed on
astrocytes and neurons to participate in the development
and maintenance of chronic pain. This point needs to be
elucidated in further investigations.
The significantly superior analgesic effect of ATL com-
pared to the other drugs may have stemmed from the
trihydroxytetraene structure of native lipoxins, which is
sensitive to metabolic inactivation by dehydrogenation,
but ATL is more resistant to metabolic inactivation than
is the native LXs [21,22]. It has been reported that i.v.
treatment with LXA4, LXB4 or ATL significantly alle-
viated the heat hyperalgesia in a carrageenan-induced in-
flammatory pain model [24]. The present study revealed
similar effects of LXs and analogues on CIBP.
Furthermore, repeated i.t. injection of ATL had a thera-
peutic analgesic effect on neuropathic pain in a chronic
compression of dorsal root ganglia (CCD) model [23].
Since the multiple effects of LXs and analogues include
Figure 5 Photomicrographs showing the expression of CD11B (microglial marker) (green) and ALX (red) on the dorsal horn of the
ipsilateral spinal cord of rats. Immunohistological processing of spinal cord sections from the naive (A-C), sham (D-F) and cancer (G-I) groups
showed no co-localization of ALX-like immunoreactivity and the microglial marker CD11B (n=4). Bar 100 μm. ALX, lipoxin A4 receptor.
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anti-inflammatory and anti-cancer effects [36-38], the pos-
sible therapeutic effect of chronic systemic administration
of LXs and analogues needs to be assessed soon.
Early reports demonstrated that LXs play an important
role in pain processing by regulating communication be-
tween the immune and sensory nervous systems [39],
which has been supported by research regarding the anal-
gesic effects of LXs on inflammation pain and neuropathic
pain [23,24,40]. It has been reported that LXA4 and ATL
could interfere with the mitogen-activated protein kinase
(MAPK) signaling pathway, inhibit the activation of NF-
kappa B and AP-1, and consequently control the expres-
sion of pro-inflammatory cytokines [21,22,41]. Therefore,
ATL may alleviate mechanical allodynia in CIBP by inhi-
biting the MAPK signaling pathway and NF-kappa B acti-
vation to inhibit the production of pro-inflammatory
mediators. However, our current in vivo study revealed lit-
tle effect of ATL on the spinal MPAK signaling pathways
(data not shown). These warrant further study and invitro
studies are underway by culturing spinal neurons and glial
cells, respectively.
Interestingly, it has been reported that an LX analogue
can elevate the mRNA of both suppressors of cytokine
signaling–1 (SOCS-1) and SOCS-2, two of the endogen-
ous inhibitors of cytokine-elicited signaling pathways, in
the kidney in ischemic acute renal failure in mice [42].
Our preliminary experiments showed that ATL-treated
rats also displayed increased spinal mRNA levels for
SOCS-1 (data not shown). Since the putative role for
SOCSs as endogenous inhibitors of cytokine bioactivities
transduced through JAK-STAT signal transduction path-
ways [43,44], the finding of decreased mRNA levels for
IL-1β, IL-6 and TNF-α in association with increased
expression of SOCS-1 suggests a possible mechanism
through which lipoxins could modulate cytokine bioactiv-
ity and, hence, attenuate spinal neuroinflammation condi-
tions in rats with CIBP. The LXs may exert their analgesic
effect through the ALX on astrocytes and neurons via its
multipronged effects on the neuroinflammation milieu as
well as neural activity in the spinal cord. However, our
in vivo study revealed little effect of ATL on these signal
pathways (data not shown). These warrant further study
and in vitro studies are being conducted by culturing
spinal neurons and glial cells, respectively.
Taken together, the results of the present study demon-
strated for the first time that i.t. injection with LXs could
strongly attenuate the mechanical allodynia in CIBP. The
increased expression of pro-inflammatory mediators in
CIBP was significantly attenuated by i.t.ATL. This study
indicates that LXs and analogues could alleviate CIBP with
sustained efficacy and these findings point to novel thera-
peutic targets for analgesia in CIBP.
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